Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
NovoCureNVCR | Open-market sale | 06/04 | 06/05 | 34,273 sh | $17.93 | $614,514.89 | −6.9% | |
Jeryl L. HillemanDirector | NovoCureNVCR | Open-market sale | 06/02 | 06/03 | 2,945 sh | $15.77 | $46,442.65 | −17.5% |
Gabriel LeungDirector | NovoCureNVCR | Open-market sale | 06/02 | 06/03 | 2,945 sh | $15.77 | $46,442.65 | −3.2% |
David HungDirector | NovoCureNVCR | Open-market sale | 06/02 | 06/03 | 2,945 sh | $15.77 | $46,442.65 | −12.6% |
W. Anthony VernonDirector | NovoCureNVCR | Open-market sale | 06/02 | 06/03 | 2,945 sh | $15.77 | $46,442.65 | −1.5% |
Timothy J. ScannellDirector | NovoCureNVCR | Open-market sale | 06/02 | 06/03 | 2,945 sh | $15.77 | $46,442.65 | −17.1% |
Allyson J. OceanDirector | NovoCureNVCR | Open-market sale | 06/02 | 06/03 | 2,945 sh | $15.77 | $46,442.65 | −20.6% |
Kristin StaffordDirector | NovoCureNVCR | Open-market sale | 06/02 | 06/03 | 2,945 sh | $15.77 | $46,442.65 | −20.6% |
NovoCureNVCR | Open-market sale | 03/04–03/05 | 03/05 | 48,623 sh2 trades | $13.72avg. | $667,065.29 | −40.0% | |
Uri WeinbergChf Medical and Innovation Ofr | NovoCureNVCR | Open-market sale | 03/04 | 03/05 | 6,412 sh | $13.31 | $85,343.72 | −2.3% |
NovoCureNVCR | Open-market sale | 03/04 | 03/05 | 5,607 sh | $13.31 | $74,629.17 | −1.1% | |
Michal Nath PuriChief Human Resources Officer | NovoCureNVCR | Open-market sale | 03/04 | 03/05 | 1,100 sh | $13.31 | $14,641 | −0.5% |
Nicolas LeupinFormer Chief Medical Officer | NovoCureNVCR | Open-market sale | 03/04 | 03/05 | 1,100 sh | $13.31 | $14,641 | −1.1% |
NovoCureNVCR | Open-market sale | 03/04 | 03/05 | 6,412 sh | $13.31 | $85,343.72 | −3.4% | |
NovoCureNVCR | Open-market sale | 03/03 | 03/05 | 71,887 sh2 trades | $12.98avg. | $933,085.93 | −18.0% | |
NovoCureNVCR | Open-market sale | 02/27–03/02 | 03/03 | 10,733 sh2 trades | $13.68avg. | $146,876 | −4.6% | |
NovoCureNVCR | Open-market sale | 02/27–03/02 | 03/03 | 16,966 sh2 trades | $13.59avg. | $230,526.12 | −4.6% | |
NovoCureNVCR | Open-market sale | 02/27–03/02 | 03/03 | 1,963 sh2 trades | $13.62avg. | $26,745.22 | −2.5% | |
Michal Nath PuriChief Human Resources Officer | NovoCureNVCR | Open-market sale | 02/27 | 03/03 | 1,441 sh | $13.66 | $19,684.06 | −0.9% |
Nicolas LeupinFormer Chief Medical Officer | NovoCureNVCR | Open-market sale | 02/27 | 03/03 | 1,029 sh | $13.66 | $14,056.14 | −1.0% |